WallStSmart

Axon Enterprise Inc. (AXON)vsNorthrop Grumman Corporation (NOC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Northrop Grumman Corporation generates 1409% more annual revenue ($41.95B vs $2.78B). NOC leads profitability with a 10.0% profit margin vs 4.5%. AXON appears more attractively valued with a PEG of 1.65. NOC earns a higher WallStSmart Score of 56/100 (C).

AXON

Hold

38

out of 100

Grade: F

Growth: 7.3Profit: 3.0Value: 4.7Quality: 6.3
Piotroski: 3/9Altman Z: 1.78

NOC

Buy

56

out of 100

Grade: C

Growth: 6.0Profit: 7.5Value: 6.7Quality: 6.0
Piotroski: 3/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AXONSignificantly Overvalued (-4130.3%)

Margin of Safety

-4130.3%

Fair Value

$10.27

Current Price

$460.15

$449.88 premium

UndervaluedFair: $10.27Overvalued
NOCUndervalued (+24.9%)

Margin of Safety

+24.9%

Fair Value

$904.35

Current Price

$691.21

$213.14 discount

UndervaluedFair: $904.35Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AXON1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
38.5%10/10

Revenue surging 38.5% year-over-year

NOC3 strengths · Avg: 8.7/10
Market CapQuality
$97.36B9/10

Large-cap with strong market position

Return on EquityProfitability
26.2%9/10

Every $100 of equity generates 26 in profit

Free Cash FlowQuality
$3.23B8/10

Generating 3.2B in free cash flow

Areas to Watch

AXON4 concerns · Avg: 3.8/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

Price/BookValuation
11.4x4/10

Trading at 11.4x book value

Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

Return on EquityProfitability
4.5%3/10

ROE of 4.5% — below average capital efficiency

NOC4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
5.362/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : AXON

The strongest argument for AXON centers on Revenue Growth. Revenue growth of 38.5% demonstrates continued momentum.

Bull Case : NOC

The strongest argument for NOC centers on Market Cap, Return on Equity, Free Cash Flow.

Bear Case : AXON

The primary concerns for AXON are PEG Ratio, Price/Book, Altman Z-Score. A P/E of 302.4x leaves little room for execution misses. Thin 4.5% margins leave little buffer for downturns.

Bear Case : NOC

The primary concerns for NOC are Altman Z-Score, Debt/Equity, Piotroski F-Score.

Key Dynamics to Monitor

AXON profiles as a hypergrowth stock while NOC is a value play — different risk/reward profiles.

AXON carries more volatility with a beta of 1.52 — expect wider price swings.

AXON is growing revenue faster at 38.5% — sustainability is the question.

NOC generates stronger free cash flow (3.2B), providing more financial flexibility.

Bottom Line

NOC scores higher overall (56/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Axon Enterprise Inc.

INDUSTRIALS · AEROSPACE & DEFENSE · USA

Axon Enterprise, Inc. develops, manufactures, and sells conducted energy weapons (DEC) under the TASER brand name in the United States and internationally. The company is headquartered in Scottsdale, Arizona.

Northrop Grumman Corporation

INDUSTRIALS · AEROSPACE & DEFENSE · USA

Northrop Grumman Corporation (NYSE: NOC) is an American multinational aerospace and defense technology company.

Visit Website →

Want to dig deeper into these stocks?